Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Marcellin

Showing results (181-190 of 212) with videos related to

Pageof 22
Sort By:
Gut|October 23, 2003
Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis CT Asselah, N Boyer, M-C Guimont, et al.
Journal of Viral Hepatitis|October 10, 2012
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirinS Zeuzem, M Rodríguez-Torres, K Rajender Reddy, et al.
Journal of Viral Hepatitis|March 6, 2002
Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosisManuela G Neuman, J P Benhamou, I M Malkiewicz, et al.
Hepatology (Baltimore, Md.)|April 16, 1998
Re-treatment with interferon alfa of patients with chronic hepatitis CW C Chow, N Boyer, M Pouteau, et al.
Journal of Viral Hepatitis|October 15, 2013
IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patientsQ Zhang, M Lapalus, T Asselah, et al.
Ugeskrift for Laeger|October 15, 1998
[Pretreatment with prednisolone enhances the effect of human lymphoblastoid interferon in chronic hepatitis B]K Krogsgaard, P Marcellin, C Trepo, et al.
Journal of Hepatology|December 1, 1996
Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial GroupK Krogsgaard, P Marcellin, C Trepo, et al.
Journal of Viral Hepatitis|March 13, 2012
Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis CM Sasso, I Tengher-Barna, M Ziol, et al.
Alimentary Pharmacology & Therapeutics|March 28, 2008
Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis BS G Lim, N Leung, H W L Hann, et al.
Journal of Viral Hepatitis|June 20, 2007
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infectionD Roulot, V Bourcier, V Grando, et al.
Pageof 22

Showing results (181-190 of 212) with videos related to

Sort By:
Pageof 22
Gut|October 23, 2003
Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis CT Asselah, N Boyer, M-C Guimont, et al.
Journal of Viral Hepatitis|October 10, 2012
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirinS Zeuzem, M Rodríguez-Torres, K Rajender Reddy, et al.
Journal of Viral Hepatitis|March 6, 2002
Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosisManuela G Neuman, J P Benhamou, I M Malkiewicz, et al.
Hepatology (Baltimore, Md.)|April 16, 1998
Re-treatment with interferon alfa of patients with chronic hepatitis CW C Chow, N Boyer, M Pouteau, et al.
Journal of Viral Hepatitis|October 15, 2013
IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patientsQ Zhang, M Lapalus, T Asselah, et al.
Ugeskrift for Laeger|October 15, 1998
[Pretreatment with prednisolone enhances the effect of human lymphoblastoid interferon in chronic hepatitis B]K Krogsgaard, P Marcellin, C Trepo, et al.
Journal of Hepatology|December 1, 1996
Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial GroupK Krogsgaard, P Marcellin, C Trepo, et al.
Journal of Viral Hepatitis|March 13, 2012
Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis CM Sasso, I Tengher-Barna, M Ziol, et al.
Alimentary Pharmacology & Therapeutics|March 28, 2008
Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis BS G Lim, N Leung, H W L Hann, et al.
Journal of Viral Hepatitis|June 20, 2007
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infectionD Roulot, V Bourcier, V Grando, et al.
Pageof 22